Other information
Gender equality index 2019 Gender equality index
Gender equality index 2019 Gender equality index
Mast cell tumours (MCTs) are the most common cutaneous malignancies in dogs. Masivet® is an effective, well-tolerated and proven treatment for dog MCT and was the first tyrosine kinase inhibitor registered in veterinary oncology when it was approved by the European Medicine Agency in 2008. AB Science celebrated in 2018 the 10th anniversary of the…
“AB Science was founded in 2001 by a team of scientists in order to develop new drugs targeting indications with unmet medical needs, in the field of cancers, chronic inflammatory diseases and neurological degenerative disorders. In human medicine, our masitinib pipeline is well advanced with several phase 3 studies in oncology and non-oncology diseases and…
Masitinib, AB Science main compound, is a selective tyrosine kinase inhibitor which is currently developed in three therapeutic areas: neurology, inflammatory diseases and oncology. As of today, masitinib is mainly developed in the following indications: amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer disease, mastocytosis, severe asthma, prostate cancer and pancreatic cancer. Masitinib pipeline is well advanced with…